

Stephanie M De Boer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6441104/publications.pdf>

Version: 2024-02-01

26
papers

1,992
citations

516681

16
h-index

642715

23
g-index

30
all docs

30
docs citations

30
times ranked

1832
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 390-399.	0.8	12
2	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. <i>Nature Communications</i> , 2022, 13, 1373.	12.8	47
3	p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. <i>Modern Pathology</i> , 2022, 35, 1475-1483.	5.5	39
4	Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 594-604.	2.5	78
5	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 975-986.	0.8	20
6	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1212-1220.	6.3	47
7	Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review. <i>Radiotherapy and Oncology</i> , 2021, 164, 128-137.	0.6	25
8	PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. <i>Cancers</i> , 2021, 13, 5179.	3.7	7
9	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3388-3397.	1.6	398
10	Prevalence and prognosis of lynch syndrome and sporadic mismatch repair deficiency in the combined PORTEC-1,-2 and -3 endometrial cancer trials. , 2020, , .		1
11	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1273-1285.	10.7	305
12	Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy. <i>Annals of Oncology</i> , 2019, 30, v899-v900.	1.2	15
13	Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S1-S2.	0.8	1
14	Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial. , 2019, , .		1
15	Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 51-60.	2.4	12
16	Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. <i>Annals of Oncology</i> , 2018, 29, 424-430.	1.2	71
17	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 295-309.	10.7	426
18	Investigators' response. <i>Lancet Oncology</i> , The, 2018, 19, 602.	10.7	0

#	ARTICLE	IF	CITATIONS
19	Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. <i>British Journal of Cancer</i> , 2018, 119, 1067-1074.	6.4	171
20	OC-0323: Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, S171-S172.	0.6	0
21	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5502-5502.	1.6	23
22	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1114-1126.	10.7	135
23	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 797-809.	0.8	96
24	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5501-5501.	1.6	2
25	Non-invasive computed tomography coronary angiography as a gatekeeper for invasive coronary angiography. <i>International Journal of Cardiovascular Imaging</i> , 2013, 29, 221-228.	1.5	16
26	Impact of Clinical Presentation and Pretest Likelihood on the Relation Between Calcium Score and Computed Tomographic Coronary Angiography. <i>American Journal of Cardiology</i> , 2010, 106, 1675-1679.	1.6	39